Kura Oncology, Inc. Net Income Loss

• Kura Oncology, Inc. showed a decrease of -60.2% in Net Income Loss from 2024 to 2025.
• This data is from Kura Oncology, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
• XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 18 years of available data (2008 to 2025), Kura Oncology, Inc.'s Net Income Loss has declined by 828,695.8%.
• Historical annual values: Fiscal year 2025: -$278.67 million | Fiscal year 2024: -$173.98 million | Fiscal year 2023: -$152.63 million | Fiscal year 2022: -$135.84 million | Fiscal year 2021: -$130.47 million | Fiscal year 2020: -$89.63 million | Fiscal year 2019: -$63.14 million | Fiscal year 2018: -$60.45 million | Fiscal year 2017: -$35.43 million | Fiscal year 2016: -$27.56 million | Fiscal year 2015: -$22.63 million | Fiscal year 2014: -$30.7 thousand | Fiscal year 2013: -$28.6 thousand | Fiscal year 2012: -$27.3 thousand | Fiscal year 2011: -$27.0 thousand | Fiscal year 2010: -$22.4 thousand | Fiscal year 2009: -$20.0 thousand | Fiscal year 2008: -$33.6 thousand.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026